Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma
Status:
Completed
Trial end date:
2017-02-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and potential effectiveness of a new
treatment for advanced and recurrent melanoma involving the combination of Ipilimumab and
IFN-α2b before surgery and to test for biomarker studies in blood and/or tumor to better
understand this disease, how best to treat it and what patients should be treated with this
combination.